![](https://endpts.com/wp-content/uploads/2020/10/Danny-Bar-Zohar-via-Novartis-on-Twitter-scaled.jpg)
Danny Bar-Zohar
Novartis vet Danny Bar-Zohar leaps back into R&D, taking over the development team at Merck KGaA as Luciano Rossetti steps out
After a brief stint as a biotech investor at Syncona, Novartis vet Danny Bar-Zohar is back in R&D, and he’s taking the lead position at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.